I joined Genentech in 2011. As a Senior Scientist in the Department of Oncology Biomarker at Genentech, my group focuses on understanding the disease biology of ovarian cancer and developing biomarker strategies to enable targeted therapy (i.e. Antibody-Drug Conjugates, cancer immunotherapies) for this disease area. More recently, my group’s research interests also extend to understanding the tumor stroma biology and its interplay with anti-cancer immunity and response to immunotherapy. I am also passionate about technology development, leading efforts in developing and applying cancer genomics, next generation sequencing and single cell analysis for clinical biomarker development. Prior to joining Genentech in 2011, I led a R&D team to develop innovative genomic technologies and applications for cancer biomarker discovery and stem cell research at Applied Biosystems.
Becoming a postdoc mentor has been the most exciting and rewarding experience for me. The postdoc program provides us an excellent opportunity to explore uncharted area in drug development and dive in deeper into disease biology and mechanism studies.
Clin Cancer Res. 2015 Jul 1;21(13):2941-51.
Clin Cancer Res. 2014 Apr 15;20(8):2080-91.
My group’s research interests focus on characterizing the roles of tumor stroma in promoting drug resistance and immune privilege. Particularly, we are interested in mechanistically characterizing roles of tumor stroma as a cancer stem cell niche for promoting drug resistance and how tumor stroma mediates T cell or myeloid cell trafficking, activation and differentiation. We are also interested in developing applications of single cell sequencing technology for immunophenotyping in a patient’s tumor microenvironment.